TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02375425

Intervention type: OTHER
Intervention: no intervention
Description: no intervention-specimen collection study only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention-specimen collection study only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention-specimen collection study only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention-specimen collection study only
Study: NCT01156909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period.
Study: NCT03817099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention based on My Dia-RNP
Description: Subjects in this group will be advised to follow My Dia-RNP and to incorporate diabetes-specific formula (Nutren®Untuk Diabetik)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects in the group continue with the usual care
Study: NCT02357056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wet Lab
Description: ITA dissection and Annuloplasty Sutures in porcine model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Lab
Description: Camera and clutching, peg transferring, intracorporeal knot tying

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: daVinci Surgical Skills simulation
Study: NCT01238341

Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Description: An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
Study: NCT01589588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open Hudson Mask
Description: Mask type 1 oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cluster headache mask with 3 L reservoir
Description: Mask type 2 with oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask 3
Description: Mask type 3 oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carnét oxygen demand valve
Description: mask type 3 oxygen

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Carnét oxygen demand valve
Description: mask type 3 placebo
Study: NCT04690335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-012-968
Description: MV-012-968 is a recombinant, live attenuated RSV vaccine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT02117219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 Evaluate MEDI4736 in MDS
Description: MEDI4736 will be administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIDAZA
Description: VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIDAZA
Description: VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: tremelimumab will be administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: tremelimumab will be administered by IV infusion
Study: NCT03300414

Intervention type: OTHER
Intervention: One time blood draw
Description: Same as part 1
Study: NCT06019026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri-Lock
Description: Implant Stem

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summit
Description: Implant Stem
Study: NCT03612479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDFIT Healthy
Description: The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KIDFIT Safe
Description: The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
Study: NCT01393418

Intervention type: OTHER
Intervention: Cardiac Surgery
Study: NCT01549834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: High Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT00780559

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Diet and Physical Activity
Description: Subjects will receive an individually tailored diet and physical activity enhancement program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
Study: NCT03362385

Intervention type: OTHER
Intervention: Patients with OSA based on sleep study
Description: Polysomnography or Polygraphy

Intervention type: OTHER
Intervention: Patients without OSA based on sleep study
Description: Polysomnography or Polygraphy
Study: NCT01495572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV (in the vein) for 5 days (day -5 to -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV (in the vein) for 5 days (day -5 to -1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV (in the vein) for days -7 and -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV (in the vein) for days -7 and -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1 Reactive CD8+ PBL
Description: Intravenous (IV) over 30 minutes on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1 Reactive CD8+ PBL
Description: Intravenous (IV) over 30 minutes on day 0
Study: NCT04577053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device
Description: Manufactured by QX World Ltd. in Budapest, Hungary
Study: NCT00312598

Intervention type: DRUG
Intervention: Aripiprazole
Study: NCT01327846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
Study: NCT02623751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2375
Description: KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily.
Study: NCT02784964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elixcyte 8 ml
Description: ADSC 6.4\*10\^7 cells, allogeneic injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hya Joint Plus
Description: Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elixcyte 4 ml
Description: ADSC 3.2\*10\^7 cells, allogeneic injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elixcyte 2 ml
Description: ADSC 1.6\*10\^7 cells, allogeneic injection
Study: NCT01262547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabrasion-Micrografting
Description: Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Only dermabrasion (removal of epidermis) alone will be done at baseline.
Study: NCT00636740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 20mg Tablets
Description: Oral enteric coated tablets, 20mg, weekly, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 20mg Tablets
Description: Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
Study: NCT01888549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose PPI
Description: :40mg, po(per oral) 2times.day, 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard PPI
Description: : 40mg, po(per oral) 1times.day, 8weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01064700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Litebook Bright Light Box
Description: Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Litebook inactivated negation ion generator (the placebo)
Description: Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
Study: NCT02919553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified wet-suction technique
Description: Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capillary slow pull technique
Description: The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
Study: NCT04033965

Intervention type: GENETIC
Intervention: Corellation of Mutations, TILs and Age in Breast Cancer

Intervention type: GENETIC
Intervention: Corellation of Mutations, TILs and Age in Breast Cancer
Study: NCT04562740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABLUMINUS DES drug eluting stent
Description: Following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), the ABLUMINUS stent will be deployed at the lesion as per Instructions for Use (IFU) after appropriate sizing using the diameter of the plain balloon angioplasty. After deployment of the ABLUMINUS stent, further balloon angioplasty of the stent will be performed, using the same diameter standard balloon catheter at 2 minutes inflation, to ensure adequate moulding and expansion of the stent.
Study: NCT03742375

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV genotyping
Description: Quantitative HPV genotyping on anal swab
Study: NCT00735280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: bolus of 100 U/kg of unfractionated heparin
Study: NCT03507907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization for Study Group
Description: Mulligan Mobilization techniques were applied to the older adults who included in study group.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy for Control Group
Description: Conventional therapy was applied to the older adults who included in control group.
Study: NCT04310293

Intervention type: OTHER
Group type: OTHER
Intervention: Femara,Grotwth hormone,HMG
Description: NOVEL THERAPY
Study: NCT02844270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Description: Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Study: NCT02487043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A telephone-based case-management intervention
Description: Regular Telephone support delivered by Health coaches
Study: NCT01462006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: randomized to drug or placebo, followed by washout, followed by crossover

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomized to drug or placebo, followed by washout, followed by crossover
Study: NCT02963662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass was one of the interventions pre-specified to be administered to participants. The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy was the other intervention pre-specified to be administered to participants. The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
Study: NCT02097589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: Pneumovax 23 injected once, intramuscularly at Day 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumovax 23
Description: Pneumovax 23 injected once, intramuscularly at Day 7.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (lactose pill)
Description: 10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
Study: NCT02112409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cell salvage technique
Description: blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cell salvage technique
Description: blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute normovolemic hemodilution
Description: Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
Study: NCT00481364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 40 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tb/day
Study: NCT00574691

Intervention type: DEVICE
Group type: OTHER
Intervention: 7F Ensure Medical Vascular Closure Device
Description: Vascular Closure Device
Study: NCT05731752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX009
Description: The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
Study: NCT04209907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retrolaminar block tecnique
Description: By using ultrasound probe, the needle with in-plane , after seeing vertebral lamina, the local anesthetic will injectate
Study: NCT01471444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
Study: NCT00390312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Oral placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous placebo
Description: Intravenous placebo
Study: NCT00912392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar® 7.5mg/m2 on day 1 to day 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide-Carboplatin
Description: Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide-Carboplatin
Description: Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
Study: NCT00996606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
Study: NCT01471444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
Study: NCT00713505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).